|
|
Vaccine Detail
|
TLR-9/GM Vaccine |
| Vaccine Information |
- Vaccine Name: TLR-9/GM Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007113
- Type: Peptide vaccination
- Status: Research
- Antigen: MART-1, gp100, tyrosinase (Tarhini et al., 2012)
- Immunization Route: Intramuscular injection (i.m.)
- Description: This is for Melanoma Cancer (Tarhini et al., 2012).
|
| Host Response |
|
Human Response
- Vaccine Immune Response Type: VO_0003057
- Immune Response: There were no significant changes in the percentage of T-reg or MDSC between baseline and day 50 or day 90, except for a trend (p=0.07) towards a decreased percentage of monocyte gate MDSC (HLA-DR+ low/CD14+) at day 50 as illustrated in Figure 3. There were no significant correlations between the changes in MDSC or T-reg and clinical outcome (Tarhini et al., 2012)
|
| References |
Tarhini et al., 2012: Tarhini AA, Butterfield LH, Shuai Y, Gooding WE, Kalinski P, Kirkwood JM. Differing patterns of circulating regulatory T cells and myeloid-derived suppressor cells in metastatic melanoma patients receiving anti-CTLA4 antibody and interferon-α or TLR-9 agonist and GM-CSF with peptide vaccination. Journal of immunotherapy (Hagerstown, Md. : 1997). 2012; 35(9); 702-710. [PubMed: 23090079].
|
|
